Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Locatelli

Showing results (51-60 of 64) with videos related to

Pageof 7
Sort By:
Journal of Environmental Management|January 1, 2026
Simulating climate change impacts on soil carbon storage in agroecosystems from Brazilian drylandsLucas T Greschuk, Stephen Ogle, Jorge L Locatelli, et al.
International Journal of Cancer|May 29, 2014
YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulationMarzia Pennati, Stefania Sbarra, Michelandrea De Cesare, et al.
Anticancer Research|January 30, 2022
The Natural Estrogen Receptor Beta Agonist Silibinin as a Promising Therapeutic Tool in Diffuse Large B-cell LymphomaElena Ortona, Silvia L Locatelli, Maria Teresa Pagano, et al.
Oncotarget|January 5, 2017
Estrogen receptor β ligation inhibits Hodgkin lymphoma growth by inducing autophagyMarina Pierdominici, Angela Maselli, Silvia L Locatelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2018
Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3Kδ/γ Inhibitor RP6530Silvia L Locatelli, Giuseppa Careddu, Simone Serio, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 26, 2019
A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European StudyCarmelo Carlo-Stella, Richard Delarue, Lydia Scarfo, et al.
Cell Death and Differentiation|December 20, 2014
DOT1L-mediated H3K79me2 modification critically regulates gene expression during cardiomyocyte differentiationP Cattaneo, P Kunderfranco, C Greco, et al.
Cancer|May 14, 2011
Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemiaAnna Guidetti, Carmelo Carlo-Stella, Marco Ruella, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2014
Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseasesAnna Guidetti, Carmelo Carlo-Stella, Silvia L Locatelli, et al.
Bone Reports|January 16, 2020
Generation of an immunodeficient mouse model of tcirg1-deficient autosomal recessive osteopetrosisEleonora Palagano, Sharon Muggeo, Laura Crisafulli, et al.
Pageof 7

Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
Journal of Environmental Management|January 1, 2026
Simulating climate change impacts on soil carbon storage in agroecosystems from Brazilian drylandsLucas T Greschuk, Stephen Ogle, Jorge L Locatelli, et al.
International Journal of Cancer|May 29, 2014
YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulationMarzia Pennati, Stefania Sbarra, Michelandrea De Cesare, et al.
Anticancer Research|January 30, 2022
The Natural Estrogen Receptor Beta Agonist Silibinin as a Promising Therapeutic Tool in Diffuse Large B-cell LymphomaElena Ortona, Silvia L Locatelli, Maria Teresa Pagano, et al.
Oncotarget|January 5, 2017
Estrogen receptor β ligation inhibits Hodgkin lymphoma growth by inducing autophagyMarina Pierdominici, Angela Maselli, Silvia L Locatelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2018
Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3Kδ/γ Inhibitor RP6530Silvia L Locatelli, Giuseppa Careddu, Simone Serio, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 26, 2019
A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European StudyCarmelo Carlo-Stella, Richard Delarue, Lydia Scarfo, et al.
Cell Death and Differentiation|December 20, 2014
DOT1L-mediated H3K79me2 modification critically regulates gene expression during cardiomyocyte differentiationP Cattaneo, P Kunderfranco, C Greco, et al.
Cancer|May 14, 2011
Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemiaAnna Guidetti, Carmelo Carlo-Stella, Marco Ruella, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2014
Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseasesAnna Guidetti, Carmelo Carlo-Stella, Silvia L Locatelli, et al.
Bone Reports|January 16, 2020
Generation of an immunodeficient mouse model of tcirg1-deficient autosomal recessive osteopetrosisEleonora Palagano, Sharon Muggeo, Laura Crisafulli, et al.
Pageof 7